Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Estrogen receptors α, β and GPER in the CNS and trigeminal system - molecular and functional aspects

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. PACAP38 and PAC receptor blockade: a new target for headache?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The chronobiology of migraine: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Triptans are effective and well tolerated in acute migraine management but their exact mechanism of action is still debated. Triptans might exert their antimigraine effect by reducing the levels of circulating calcitonin gene-related peptide (CGRP). To examine this question, we examined whether sumatriptan modulate the baseline CGRP levels in vivo, under conditions without trigeminovascular system activation. We sampled blood from the internal and external jugular, the cubital veins, and the radial artery before and after administration of subcutaneous sumatriptan in 16 healthy volunteers. Repeated-measure ANOVA showed no interaction between catheter and time of sampling and thus no significant difference in CGRP between the four catheters (P=0.75). CGRP did not change over time in the four compartments (P>0.05). The relative changes in CGRP between baseline and maximal sumatriptan concentration did not differ between the four vascular compartments (P=0.49). It was found that Sumatriptan did not change the levels of circulating CGRP in the intra or extracerebral circulation in healthy volunteers. This speaks against a direct CGRP-reducing effect of sumatriptan in vivo in humans when the trigemino vascular system is not activated.
Original languageEnglish
JournalJournal of Headache and Pain
Volume10
Issue number2
Pages (from-to)85-91
Number of pages6
ISSN1129-2369
DOIs
Publication statusPublished - 2009

Bibliographical note

Keywords: Adult; Analysis of Variance; Calcitonin Gene-Related Peptide; Cerebrovascular Circulation; Female; Humans; Injections, Subcutaneous; Male; Radioimmunoassay; Serotonin Agonists; Sumatriptan; Young Adult

ID: 172086